Go To Global Site
Welcome to UCB in the United States

Oct

16

Update on U.S. FDA Review of Biologics License Application (BLA) for bimekizumab

Sep

29

New Bimekizumab Two-Year Data in Moderate to Severe Plaque Psoriasis Presented at the 30th European Academy of Dermatology and Venereology Congress

Aug

30

UCB Announces BRIVIACT® (brivaracetam) CV Now FDA-Approved to Treat Partial-Onset Seizures in Pediatric Patients One Month of Age and Older

Apr

28

UCB Announces PDUFA Date for Bimekizumab

Apr

23

"The New England Journal of Medicine" Publishes Results from Two Bimekizumab Phase 3 Studies in Moderate to Severe Plaque Psoriasis

Apr

23

UCB to Present 12 Abstracts on Bimekizumab at AAD VMX 2021

UCB to Present 12 Abstracts on Bimekizumab at AAD VMX 2021 

Feb

25

UCB - Sustaining Growth, Now and Into the Future

Dec

03

UCB Demonstrates Commitment to Science and Discovery Across Its Epilepsy Portfolio at the American Epilepsy Society’s Virtual Event AES2020

  • 15 scientific presentations highlight data on BRIVACT® (brivaracetam) CV, NAYZILAM® (midazolam) nasal spray CIV, VIMPAT® (lacosamide) CV, and others, illustrating UCB’s commitment to developing new treatment options for patients in their treatment journey
  • UCB’s VIMPAT, recently approved by the U.S. Food and Drug Administration (FDA) as adjunctive therapy in the treatment of primary generalized tonic-clonic seizures (PGTCS), will be highlighted during virtual symposium featuring expert neurology panel

Nov

30

World's Leading Life Science Companies Now Enrolling COMMUNITY, a Global, Platform Trial for Hospitalized Patients with COVID-19

Nov

12

UCB strengthens its gene therapy activities with additional pipeline programs, capabilities and platforms